Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, is pleased to announce the appointment of Neil Thompson, PhD, as Chief Scientific Officer (CSO).
Dr Neil Thompson appointed CSO of Healx to spearhead drug discovery expansion
Dr Neil Thompson will spearhead the expansion of the drug discovery and development team at Healx, as the company continues its growth as a leading AI-powered, next-generation biopharmaceutical company. Healx is pioneering in that it takes a patient-first approach and integrates AI, deep pharmacology expertise, and patient engagement to intelligently match treatments to disease patients.
Neil brings over 30 years of experience in the biotech and pharmaceutical industries and a strong background working across a breadth of disease areas. Across his three-decades-long career, he has been involved in progressing more than 10 drugs into patients and has led a number of drug discovery projects across a variety of therapeutic areas (cardiovascular, neurology, inflammation and oncology).
Neil was Senior Vice President of Biology at Astex Pharmaceuticals for 15 years, a Cambridge, UK-based biopharmaceutical company, leading the biology and pre-clinical teams whose work has resulted in two new cancer drugs reaching the market in the last two years: Kisqali (targeted for breast cancer) which came to market through Novartis in 2017; and Balversa (first targeted drug for bladder cancer) which gained market approval this year for J&J’s Janssen.
Since leaving Astex in 2017, Neil has been working as a consultant advising biotech companies from around the globe on their drug discovery and development strategies. His earlier career included Director of the Immunology Platform at multinational pharmaceutical company GlaxoSmithKline (GSK), where his area of primary responsibility was specialist cellular and molecular immunology employed in the drug development process.
Neil is Deputy Chair of the UK MRC DPFS panel and Chair of the MRC CLD/ADI committee, has authored more than 40 publications and patents, and sits on the advisory boards of several scientific institutions in the UK. He received his doctorate in Biochemistry from Kings College London.
At Healx, Neil will take on the task of building and leading a drug discovery team in-house to take drugs from prediction through to the clinical stage.
Commenting on his appointment, Dr Neil Thompson, CSO of Healx, said: “Healx’s novel approach of using AI to start with the patient as opposed to a target, is what first drew me to the company. I am excited to bring my experience to this leading AI-powered biotech that is helping patients with rare diseases. I am tremendously proud of the accomplishments to date, notably those I made during my time at Astex, and look forward to drawing on those experiences to build a team of dynamic, forward-thinking scientists, as we work to achieve our goal of progressing treatments to the clinic that can make a real difference to lives of patients.”
Dr Tim Guilliams, Healx’s Co-Founder and CEO added: "Healx is rapidly developing as a leading AI-powered biotech and I am pleased that Dr Neil Thompson, who is a world-class drug discovery expert, will lead our drug discovery and development team. Neil has an impressive track record in both large and smaller drug companies. With his expertise in drug discovery and extensive experience in leadership roles at successful organisations like Astex, Neil will be a major driver in building a pioneering team specialising in harnessing the power of AI and big data to discover treatments for rare diseases.”
For more information relating to Dr Neil Thompson's appointment as Healx CSO, please contact Healx.
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments.